Know Cancer

forgot password

CIRCCa - A Randomized Double Blind Phase II Trial of Carboplatin-Paclitaxel Plus Cediranib Versus Carboplatin-Paclitaxel Plus Placebo in Metastatic/Recurrent Cervical Cancer

Phase 2
18 Years
Open (Enrolling)
Cervical Cancer

Thank you

Trial Information

CIRCCa - A Randomized Double Blind Phase II Trial of Carboplatin-Paclitaxel Plus Cediranib Versus Carboplatin-Paclitaxel Plus Placebo in Metastatic/Recurrent Cervical Cancer



- To provide preliminary evidence regarding whether the addition of cediranib maleate to
a combination of carboplatin and paclitaxel will increase the progression-free survival
by 50% from 4 to 6 months in patients with metastatic or recurrent, undetectable
cervical carcinoma.


- To provide estimates of differences in response, survival, toxicity, quality of life,
and pharmacodynamic end-points between the study arms.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive carboplatin IV over 30-60 minutes and paclitaxel IV over 3
hours on day 1. Patients also receive oral placebo once daily.

- Arm II: Patients receive carboplatin and paclitaxel therapy as in Arm I. Patients also
receive oral cediranib maleate once daily.

In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease
progression or unacceptable toxicity. Patients with complete response, partial response, or
stable disease following completion of therapy receive cediranib maleate or placebo until
evidence of progression or toxicity.

Blood samples may be collected periodically for evaluation of the VEGFR signaling inhibitor
cediranib maleate and identification of suitable biomarkers that predict cediranib maleate
response. Quality-of-life is assessed by the EORTC QLQ-C30 and QLQ-CX24 cervix subscale
questionnaires at baseline and periodically during study and follow up.

After completion of study therapy, patients are followed up every 2 months for 3 years,
every 6 months for 2 years, and then annually thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Inclusion Criteria


- Histologically confirmed carcinoma of the cervix, including any of the following

- Squamous cell carcinoma

- Adenocarcinoma

- Adenosquamous cell carcinoma

- Must meet one of the following criteria:

- Persistent or relapsed inoperable disease after radical radiotherapy within the
irradiated pelvis

- Relapse after radical hysterectomy (after radical radiotherapy to pelvis, if

- Extra pelvic metastases

- Primary stage IVB disease

- Not suitable for potentially curative surgical procedure

- Measurable disease in ≥ 1 marker site

- No CNS disease, including brain metastases, within the past 6 months


- ECOG performance status 0-1

- Life expectancy > 12 weeks

- Hemoglobin ≥ 10 g/dL

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Calculated creatinine clearance ≥ 35 mL/min

- No proteinuria > 1+ on dipstick (on 2 consecutive dipsticks not less than 1 week
apart), unless urinary protein is < 1.5 g in a 24-hour period

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- ALT or AST ≤ 2.5 times ULN (≤ 5 times ULN if hepatic metastases present)

- Alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN if hepatic metastases present)

- Prothrombin ratio (PTR)/INR ≤ 1.5 OR PTR/INR 2.0-3.0 for patients on stable dose of

- Partial thromboplastin time < 1.2 times control

- No history of a nervous or psychiatric disorder that would prevent informed consent
and compliance

- No prior malignancy within the past 5 years, except for successfully treated basal
cell skin cancer or in-situ breast cancer

- Not pregnant or nursing

- Fertile patients must use effective contraception during and for ≥ 6 months after
completion of study treatment

- No uncontrolled infection, defined as infection that cannot be resolved readily with
antibiotics prior to trial entry

- No history of significant gastrointestinal impairment, as judged by the Investigator,
that would significantly affect the absorption of cediranib maleate

- No history of pelvic fistula

- No history of inflammatory bowel disease

- No sub-acute or acute intestinal obstruction

- No significant traumatic injury within the past 4 weeks

- No non-healing wound, ulcer, or bone fracture

- No active bleeding

- No history or evidence of thrombotic or hemorrhagic disorders

- No uncontrolled seizures, cerebrovascular accident, transient ischemic attack, or
subarachnoid hemorrhage within the past 6 months

- No significant cardiovascular disease, including any of the following:

- Arterial thrombotic event within the past 12 months

- Angina within the past 6 months

- History of poorly controlled or uncontrolled hypertension or resting BP >
150/100 mm Hg in the presence or absence of a stable regimen of
anti-hypertensive therapy within the past 6 months

- NYHA class II-IV congestive heart failure

- Peripheral vascular disease ≥ grade 3 or cardiac arrhythmia requiring medication

- Prolonged QTc (corrected) interval of > 470 ms on ECG or a family history of
long QT syndrome

- Patients with rate-controlled atrial fibrillation are eligible

- Not requiring intravenous nutritional support

- No preexisting sensory or motor neuropathy ≥ grade 2

- No history or clinical suspicion of spinal cord compression

- No known hypersensitivity to carboplatin or paclitaxel

- No evidence of any other disease, metabolic dysfunction, physical examination
finding, or laboratory finding giving reasonable suspicion of a disease or condition
that contraindicates the use of an investigational drug or puts the patient at high
risk for treatment-related complications


- See Disease Characteristics

- No unresolved toxicity ≥ CTC grade 2 from prior systemic anti-cancer therapy, except
hematological toxicity or alopecia

- No prior chemotherapy, except cisplatin administered along with radiotherapy as
primary treatment

- No major surgery within 28 days or anticipated while on study

- More than 2 weeks since prior and no concurrent potent inhibitors of CYP3A4 and 2C8,
including any of the following:

- Amiodarone

- Clarithromycin

- Erythromycin

- Simvastatin

- Atorvastatin

- Lovastatin

- Montelukast sodium

- Verapamil

- Ketoconazole

- Miconazole

- Indinavir (and other antivirals)

- Diltiazem

- No concurrent grapefruit juice or St. John wort

Type of Study:


Study Design:

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment

Outcome Measure:

Overall progression-free survival

Safety Issue:


Principal Investigator

R. Paul Symonds, MD, FRCP, FRCR

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Hospitals, Leicester



Study ID:




Start Date:

June 2010

Completion Date:

Related Keywords:

  • Cervical Cancer
  • cervical adenocarcinoma
  • cervical adenosquamous cell carcinoma
  • cervical squamous cell carcinoma
  • recurrent cervical cancer
  • stage IVB cervical cancer
  • stage IVA cervical cancer
  • Uterine Cervical Neoplasms